SWOG clinical trial number
S0349

Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) with Advanced Stage Diffuse Large B-cell NHL of Low and Low-Intermediate IPI Risk

Closed
Phase
Accrual
10%
Abbreviated Title
NON-HODGKIN'S: CHOP plus G3139 for Adv Stage Large B-cell of Low and Low-Int IPI Risk
Activated
03/01/2004
Closed
05/15/2006
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Lymphoma

Treatment

Rituximab G3139 Phosphorothioate Oligonucleotide CHOP

Eligibility Criteria Expand/Collapse

Previously untreated Stage III, IV or buly Stage II diffuse large B-cell non-Hodgkin's lymphoma (NHL); CD-20 positive; Path review required; Age < 60; IPI score of 0 or 1; bidimen meas dz; CT scan of chest and CT scan of abdomen/pelvis; bone marrow aspirate and biopsy; no clinical evidence of CNS involvement; no prior dx of indolent lymphoma; no prior chemo, RT or antibody tx for lymphoma; Zubrod PS 0-2; ejection fraction >/= 45% by MUGA or an echo with no significant abnormalities; LDH must be known; no known HIV; patients must not need supplemental oxygen.

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131